Status:
COMPLETED
Dalfampridine for Imbalance in Multiple Sclerosis
Lead Sponsor:
Oregon Health and Science University
Collaborating Sponsors:
Acorda Therapeutics
Conditions:
Multiple Sclerosis
Fatigue
Eligibility:
All Genders
20-59 years
Phase:
PHASE2
Brief Summary
Dalfampridine is a new medication that was FDA approved in 2010 to improve walking speed in people with Multiple Sclerosis (MS). People with MS walk slowly in part because MS damages the myelin insula...
Eligibility Criteria
Inclusion
- Age 20- 59 years,
- Able to walk at least 100m without an aide or with unilateral assistance
- Prolonged APR latencies (≥ 1SD \> mean for healthy people in this age range) OR,
- Reduced balance-related activity (ABC scores ≤ 85%),
- Abnormal trunk range of motion (horizontal), trunk range of motion (frontal), turning duration, cadence, double support time, stride length or gait cycle time (outside 1SD of the average for healthy people in this age range)
Exclusion
- Currently taking dalfampridine (any within the last 2 weeks),
- Cause(s) of imbalance other than MS,
- Impaired renal function (creatinine clearance ≤50mL/min),
- Seizure disorder
- Pregnancy or breast feeding
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2013
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01444300
Start Date
September 1 2011
End Date
September 1 2013
Last Update
June 16 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oregon Health and Science University
Portland, Oregon, United States, 97239